BioTech 365

MARCH 4, 2021

NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, … Continue reading → DermTech Reports Fourth Quarter and Full Year 2020 Financial Results DermTech Reports Fourth Quarter and Full Year 2020 Financial Results LA JOLLA, Calif.–(BUSINESS

Dermatology 40

Dermatology Genome Genomics 40

BioTech 365

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today … Continue reading → DermTech Announces Pricing of Public Offering of Common Stock DermTech Announces Pricing of Public Offering of Common Stock LA JOLLA, Calif.–(BUSINESS

Dermatology 40

Dermatology Genome Genomics 40

BioTech 365

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it … Continue reading → DermTech Announces Proposed Public Offering of Common Stock DermTech Announces Proposed Public Offering of Common Stock LA JOLLA, Calif.–(BUSINESS

Dermatology 40

Dermatology Genome Genomics 40

BioTech 365

JANUARY 5, 2021

NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Ray Akhavan to … Continue reading → DermTech Announces Appointment of General Counsel DermTech Announces Appointment of General Counsel LA JOLLA, Calif.–(BUSINESS

Dermatology 52

Dermatology Genome Genomics 52

BioTech 365

DECEMBER 29, 2020

NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today … Continue reading → DermTech Receives Positive Medical Coverage by Geisinger Health System DermTech Receives Positive Medical Coverage by Geisinger Health System LA JOLLA, Calif.–(BUSINESS

Dermatology 52

Dermatology Genome Genomics 52

BioTech 365

DECEMBER 28, 2020

NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that … Continue reading → DermTech Management to Present at the ICR Conference 2021 DermTech Management to Present at the ICR Conference 2021 LA JOLLA, Calif.–(BUSINESS

Dermatology 52

Dermatology Genome Genomics 52

BioTech 365

AUGUST 30, 2021

Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information … Continue reading →

Dermatology 52

Dermatology Genome Genomics 52

BioTech 365

DECEMBER 10, 2020

NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today … Continue reading → DermTech Enters Into Agreement With Blue Shield of California DermTech Enters Into Agreement With Blue Shield of California LA JOLLA, Calif.–(BUSINESS

Dermatology 40

Dermatology Genome Genomics 40

BioTech 365

NOVEMBER 4, 2020

NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that … Continue reading → –(BUSINESS WIRE)–DermTech, Inc.

Dermatology 40

Dermatology Genome Genomics 40

BioTech 365

OCTOBER 27, 2020

NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its third quarter 2020 financial results after the market closes on … Continue reading → LA JOLLA, Calif.–(BUSINESS

Dermatology 40

Dermatology Genome Genomics Marketing 40

BioTech 365

AUGUST 5, 2020

NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and unaudited financial results for the quarter ended June 30, 2020 and also provided … Continue reading → LA JOLLA, Calif.–(BUSINESS

Dermatology 40

Dermatology Genome Genomics 40

pharmaphorum

OCTOBER 5, 2022

There’s little detail on the focus of the alliance, although TrialSpark’s main focus is on rheumatology, dermatology, central nervous system, and cardiometabolic diseases. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

Pharmaceutical Technology

MAY 8, 2023

Innovation S-curve for the pharmaceutical industry Anti-viral antigen-based compositions is a key innovation area in pharmaceuticals A viral antigen is a protein encoded by the viral genome that can be detected by a specific immunological response.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

XTalks

JANUARY 2, 2024

Upon Vyjuvek’s entry into cells, the vector genome is integrated into the nucleus, initiating the transcription of the encoded human COL7A1. It is indicated for the treatment of wounds in patients aged six months and older who have DEB characterized by mutations in the collagen type VII alpha 1 chain ( COL7A1 ) gene.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

The Pharma Data

JUNE 19, 2022

This occurs occurs over time as cancer patients are treated with drugs to enhance T-cell mediated immunity,” said Gavin Robertson, professor of pharmacology, pathology, dermatology and surgery, Penn State College of Medicine.

Drugs 52

Drugs Protein Immune Response Dermatology 52

Drug Discovery World

DECEMBER 19, 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. .

Genetics 52

Genetics Drugs Development Dermatology 52

Drug Discovery World

DECEMBER 16, 2022

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia. . The top stories: .

Drugs 52

Drugs Vaccination Vaccine Genetics 52

Drug Discovery World

APRIL 15, 2024

Absci has been working within this space for a while, having recently signed deals with AstraZeneca and Almirall to discover and develop targets within oncology and dermatology, using its generative AI platform and wet lab capabilities. There are initiatives out there that are aimed at enabling greater access to data.

Antibody 59

Antibody Drugs In-Vivo Life Science 59

The Pharma Data

JANUARY 24, 2021

Quantum Genomics launched its Phase III REFRESH trial in difficult-to-treat or resistant hypertension. The drug was well tolerated and demonstrated clinically meaningful improvement in the Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure IPOEM). BT-001 is based on the patented Invir.IO

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Head and Neck Squamous Cell Cancer.

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

JULY 23, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. endocrinopathies and dermatologic reactions) are discussed below.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

JULY 8, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Head and Neck Squamous Cell Cancer.

FDA Approval 52

FDA Approval Containment Trials Genome 52

The Pharma Data

MARCH 11, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. endocrinopathies and dermatologic reactions) are discussed below.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 7, 2021 05:00 UTC. LA JOLLA, Calif.–(

Dermatology 40

Dermatology Genome Genomics Production 40

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52